Sponsor:
M.D. Anderson Cancer Center
Code:
NCT01371630
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Burkitt-Like Lymphoma With 11q Aberration
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Blinatumomab
Cyclophosphamide
Cytarabine
Dexamethasone
Inotuzumab Ozogamicin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-01-27.